Edwards Lifesciences (EW) Q1 2025: TMTT Sales Jump 60%, Fueling Portfolio-Driven Growth Outlook
Edwards Lifesciences’ first quarter showcased a portfolio firing on multiple fronts, with Transcatheter Mitral and Tricuspid Therapies (TMTT) surging 60% and new product milestones reinforcing the company’s multi-year growth thesis. Management maintained full-year guidance and offset emerging headwinds, while strategic pipeline advances and evolving reimbursement frameworks set the stage for further market expansion. Investors should focus on the interplay between regulatory catalysts, capacity investments, and the durability of innovation-led differentiation as Edwards navigates a pivotal period for structural heart therapies.
Summary
- TMTT Acceleration: Broad-based adoption of Pascal and Evoque is transforming TMTT into a material growth engine.
- Regulatory Catalysts: Multiple pipeline milestones and anticipated label expansions position Edwards for sustained category leadership.
- Margin Management: Headwinds from tariffs and acquisitions are being actively offset through disciplined cost prioritization.
Performance Analysis
Edwards delivered 8% total company sales growth to $1.41 billion, with TMTT, transcatheter mitral and tricuspid therapies, standing out as the fastest-growing segment at 60% growth, now contributing over 10% of total company sales. TAVR, transcatheter aortic valve replacement, maintained steady growth at just over 4%, with comparable performance in the US and international markets, while Surgical advanced 3% amid tougher comps and moderate procedure growth.
Gross margin held firm at 78.7%, but management flagged pressure from currency, tariffs, and the pending Genovalve acquisition. SG&A, selling, general, and administrative expenses, came in below expectations due to deferred investments, while R&D spend was reprioritized to focus on high-impact innovation. Operating margin benefited from these dynamics but is expected to face more pressure as the year progresses.
- TMTT Outperformance: Pascal and Evoque adoption drove robust growth across US and Europe, with both repair and replacement therapies gaining traction.
- TAVR Consistency: Continued Sapien platform adoption, but Japan remains a soft spot due to procedure growth and competition.
- Disciplined Expense Control: Lower-than-planned Q1 spending provided near-term EPS upside, but reinvestment is expected in coming quarters.
Cash flow remains strong, with $3 billion in cash and $300 million in Q1 buybacks, supporting ongoing capital flexibility.
Executive Commentary
"TAVR growth in the quarter was better than expected, as clinicians continue to adopt our best-in-class SAPIEN technology. Looking ahead to the rest of the year, we continue to believe that the results of the early TAVR trial represent a multi-year growth opportunity that will begin with the expected application approval in the second quarter and expand with the evolution of policy and guideline changes in the U.S. and globally."
Bernard Zavigian, CEO
"We are raising our original sales guidance range for TMTT to $550 million, driven by more favorable foreign exchange and continued business momentum... However, we do expect some pressure from the weakening dollar, the impact of announced tariffs, and the expected close of the Genovalve acquisition. We are implementing plans to mitigate these anticipated costs, and we maintain our full-year operating margin guidance."
Scott Ullam, CFO
Strategic Positioning
1. TMTT Portfolio Scale and Differentiation
Edwards is rapidly converting TMTT from a pipeline bet into a commercial growth driver, with Pascal, mitral and tricuspid repair system, and Evoque, transcatheter tricuspid valve replacement, both gaining adoption across major regions. The company’s toolbox approach—offering both repair and replacement options—uniquely positions it to address a broader patient population, especially as new indications and reimbursement policies expand access. The recent CE mark for Sapien M3, mitral valve replacement system, in Europe, and the US NCD, national coverage determination, for Evoque, provide clear runway for further penetration.
2. TAVR Resilience and Capacity Initiatives
TAVR remains the company’s anchor, with stable pricing and broad adoption of the Sapien platform. Management is actively working with hospitals to alleviate procedure capacity constraints through training, process optimization, and technology upgrades. The anticipated FDA approval for asymptomatic severe aortic stenosis is set to unlock new patient populations, while ongoing discussions around NCD revisions could further expand the addressable market and site access.
3. Surgical Innovation and Evidence
Resilia tissue technology continues to underpin Surgical’s value proposition, with new 8-year durability data and ongoing platform launches (Mitris in China, Connect in Europe) supporting the premium positioning. While growth moderated this quarter, management remains confident in mid-single-digit growth as new geographies and products ramp. The business is increasingly focused on lifetime management and evidence generation to sustain share gains in a mature market.
4. Margin Preservation Amid Headwinds
Edwards is proactively managing margin pressure from tariffs (estimated five cents EPS headwind), FX, and the Genovalve acquisition (five to ten cents EPS impact). The company is prioritizing R&D and SG&A investments, deferring lower-priority spend, and leveraging its lean manufacturing footprint to contain cost escalation. These actions allowed management to reaffirm full-year EPS guidance despite incremental headwinds.
5. Regulatory and Policy-Driven Market Expansion
Edwards is positioned to benefit from a series of regulatory and reimbursement catalysts, including FDA label expansions, CMS NCD updates, and evolving clinical guidelines. The company’s ability to educate physicians, train centers, and shape policy is central to unlocking new pools of demand, particularly in underpenetrated international markets and for new patient subgroups.
Key Considerations
This quarter’s results highlight Edwards’ transition from a single-technology leader to a diversified structural heart platform company, but also surface the operational and market complexities of scaling innovation globally.
Key Considerations:
- Pipeline to Commercial Execution: Success in TMTT hinges on physician training, payer coverage, and long-term clinical outcomes, not just regulatory milestones.
- Capacity and Referral Dynamics: TAVR growth is increasingly influenced by hospital throughput and referral education, especially as new indications come online.
- International Market Variability: Japan’s softness and Europe’s gradual M3 launch highlight the need for localized strategies and tailored market development.
- Cost Discipline vs. Growth Investment: Margin protection efforts are working, but deferred investments could become a drag if not carefully managed as competitive intensity rises.
- Regulatory and Policy Timing: Many growth levers are contingent on external regulatory actions, introducing inherent timing and adoption risk.
Risks
Key risks include regulatory delays, especially for label expansions and NCD updates, which could slow the pace of new patient adoption. Tariffs and FX remain persistent margin headwinds, and the integration of Genovalve could introduce operational complexity or distract from core execution. Competitive pressure, particularly in Japan and mature surgical markets, may require incremental investment to defend share or stimulate demand.
Forward Outlook
For Q2 2025, Edwards guided to:
- Sales of $1.45 to $1.53 billion
- Adjusted EPS of $0.59 to $0.65
For full-year 2025, management maintained guidance:
- Total company sales of $6.1 billion
- Adjusted EPS of $2.40 to $2.50
Management emphasized:
- Confidence in offsetting tariff and acquisition headwinds through disciplined expense management
- Anticipated regulatory and reimbursement catalysts expected to unlock additional growth, especially in TMTT and TAVR
Takeaways
Edwards is leveraging its diversified portfolio to drive above-market growth, with TMTT now a clear engine and TAVR poised for further expansion. Margin resilience is being achieved through targeted cost discipline, but sustained growth will require ongoing investment in market development and clinical evidence. Investors should monitor regulatory milestones, capacity expansion efforts, and the pace of international adoption as key swing factors for the next several quarters.
- Portfolio Expansion: TMTT’s rapid growth and expanding indications are reshaping Edwards’ revenue mix and long-term opportunity set.
- Execution Agility: Management’s ability to offset multiple headwinds without sacrificing innovation investment is a notable differentiator.
- Future Watchpoint: The impact of upcoming regulatory approvals and NCD revisions will be pivotal in determining whether current momentum is sustained or accelerates further.
Conclusion
Edwards Lifesciences exits Q1 with strong multi-segment momentum, a disciplined approach to headwinds, and a robust innovation pipeline. The next wave of regulatory and reimbursement catalysts will test the company’s ability to convert scientific leadership into durable, global growth.
Industry Read-Through
Edwards’ results reinforce the structural heart sector’s shift toward multi-modality portfolios and the critical role of regulatory and policy catalysts in unlocking incremental demand. The traction seen in TMTT underscores growing physician comfort with transcatheter repair and replacement therapies, setting a higher bar for competitors on both clinical evidence and commercial execution. Capacity constraints and referral dynamics are now front-and-center for all players, suggesting that future winners will be those who can scale education, training, and operational support alongside product innovation. Margin management in the face of global cost pressures is becoming a sector-wide imperative, with disciplined capital allocation increasingly separating leaders from laggards.